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The molecular events that lead to malignant transformation and subsequent
metastasis of breast carcinoma include alterations in the cells at genome,
transcriptome and proteome levels. In this study, we used publicly available gene
expression databases to identify those candidate genes which are upregulated at the
mRNA level in breast cancers but have not been systematically validated at the
protein level. Based on an extensive literature search, we identified ribosome binding
protein 1 (RRBP1) as a candidate that is upregulated at the mRNA level in five
different studies but its protein expression had not been investigated.
Immunohistochemical labeling of breast cancer tissue microarrays was carried out to
determine the expression of RRBP1 in a large panel of breast cancers. We found that
RRBP1 was overexpressed in 84% (177/219) of breast carcinoma cases tested. The
subcellular localization of RRBP1 was mainly observed to be in the cytoplasm with
intense staining in the perinuclear region. Our findings suggest that RRBP1 is an
interesting molecule that can be further studied for its potential to serve as a breast
cancer biomarker. This study also demonstrates how the integration of biological
data from available resources in conjunction with systematic evaluation approaches
can be successfully applied to clinical proteomics.
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Breast cancer is the most prevalent cancer in women and is responsible for ~450,000
deaths worldwide each year. It accounted for 23% of new cancer cases and 14% of total
cancer deaths in 2008 [1]. The molecular pathology of breast cancer has been studied
extensively over the last two decades and a large number of alterations at the molecu-
lar level have been reported by several groups. Gene expression profiling studies are a
powerful means of investigating changes in the transcriptome of cancerous cells. They
provide a broad view of the numerous candidate genes that are differentially expressed
in normal and cancerous lesions [2]. Many of these genes show significant changes in
corresponding protein expression. Large scale gene expression profiling studies have
been carried out on various subtypes of breast carcinomas by different groups [3-5].
Although these studies have reported many common genes that are significantly© 2012 Telikicherla et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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ance if the overexpression is not reflected at the protein level. Moreover, high-
throughput techniques like microarrays are associated with limitations such as experi-
mental and biological noise that necessitate further validation of the results obtained
using other relatively accurate methods. The current rush of RNA-Seq analyses will also
require the same kind of validation that mRNA transcripts are actually translated into
proteins.
Our approach in this study was to integrate data from public repositories of gene ex-
pression information and online resources of protein information coupled to literature
mining to generate a list of molecules that have been shown to be overexpressed at the
transcript level but not at the protein level. We selected RRBP1 as one such candidate
to further validate its protein expression across a panel of breast carcinomas using
immunohistochemistry.
RRBP1(Q9P2E9, ENSP00000367044.1) is an endoplasmic reticulum membrane pro-
tein [6-8] that is essential for ribosome binding and for the translocation of nascent
proteins across the membrane of the rough endoplasmic reticulum [9]. Although
RRBP1 is known to be localized primarily to the endoplasmic reticulum, it has also
been detected in the nucleus and the cytoplasm [10]. It is a 1410 amino acid protein
composed of a hydrophobic NH2-terminus that includes a transmembrane domain, a
highly conserved tandem repeat (ribosome-binding domain), and an acidic coiled-coil
COOH-terminal domain [11]. It has been shown to play an important role in pro-
collagen biosynthesis in secretory tissues and in the terminal differentiation of secretory
tissues [6,12]. It has also been shown to interact with KIF5B [13], a motor protein
highly expressed in several cancer cell lines [14]. There are limited reports on expres-
sion of this protein in cancers. In a study by Krasnov et al., it has been shown to be
overexpressed in colorectal cancers [15].
Immunohistochemistry is a robust method to validate the differential expression of
proteins at tissue level. Tissue microarray arrays (TMAs) allow the testing of a single
biomarker in a high-throughput fashion to test large number of normal and cancerous
tissues simultaneously. Using this approach, we could identify the overexpression of
RRBP1 in 84% of the breast tumors assayed. RRBP1, as a consequence of its overex-
pression, could possibly leak into blood plasma and show up at detectable levels in
breast carcinomas. We foresee that RRBP1 could be a promising biomarker if validated
in a larger cohort, especially in the plasma or serum.Results and discussion
Selection of RRBP1 as a candidate marker for evaluation
To identify novel candidate biomarkers for breast cancers, we collected information
about genes that have been reported to have significantly altered expression levels in
breast tumors. We used the online gene expression database Oncomine [16,17] to gen-
erate a list of genes which were transcriptionally upregulated in breast cancer. We next
checked the published literature to determine if they have been studied for their
expression at the protein level. The Human Protein Reference Database (HPRD) [18-
20] was next used to obtain additional information on the molecules that were short-
listed. Out of the list of genes that were transcriptionally upregulated in breast cancers
Table 1 The top ten shortlisted molecules with reports of overexpression at transcript
level but with no protein level studies in breast cancers




1 RRBP1 Ribosome binding protein 1 homolog 180 kDa 5
2 XPNPEP3 X-prolyl aminopeptidase (aminopeptidase P) 3, putative 5
3 RCOR3 REST corepressor 3 5
4 CDS2 CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 2 4
5 LSR Lipolysis stimulated lipoprotein receptor 4
6 PDE4DIP Phosphodiesterase 4D interacting protein 4
7 PGPEP1 Pyroglutamyl-peptidase I 3
8 C9ORF46 Transmembrane protein C9orf46 2
9 KIFAP3 Kinesin-associated protein 3 2
10 ZYG11A Zyg-11 homolog A 2
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dates of which are shown in Table 1, we chose RRBP1 for further evaluation. We found
five published studies that reported significant upregulation of RRBP1 at the transcript
level. A summary of results of the query we made in Oncomine is shown in Table 2.
RRBP1 was chosen as a candidate because of the availability of an antibody in the
Human Protein Atlas (HPA) [26,27] that worked in immunohistochemistry applications
and also because of it known role in tumorigenesis [15].
We next performed immunohistochemistry on tissue microarrays to test the expres-
sion of RRBP1 protein across normal breast epithelium, benign hyperplasias, in situ
carcinomas, invasive tumors and also metastatic breast cancers.RRBP1 overexpression in breast tumors
Tissue microarrays were immunohistochemically labeled using a polyclonal antibody
directed against a unique region of RRBP1. The immunogen used was a recombinant
peptide of 107 amino acids that constitutes a part of a coiled coil motif on the protein
[28]. Figure 1 shows the images of some anti-RRBP1 stained normal and breast cancer
tissue sections. The differential expression of the protein among the normal breastTable 2 Studies from ONCOMINE database showing significant upregulation of RRBP1 in
breast cancer vs normal analyses
Study Sample size Analysis type Fold
change
p-value
1. Radvanyi et al. (2005) [21] 63 Ductal Breast Carcinoma in Situ vs. Normal 3.3 p = 0.017
Invasive Mixed Breast Carcinoma vs. Normal 2.4 p = 0.013
Invasive Ductal Breast Carcinoma vs. Normal 2.2 p = 0.021
2. Finak et al. (2009) [22] 59 Invasive Breast Carcinoma Stroma vs. Normal 1.8 p = 4.75E-5
3. Perou et al. (2000) [23] 65 Lobular Breast Carcinoma vs. Normal 1.7 p = 0.046
4. Zhao et al. (2004) [24] 64 Invasive Ductal Breast Carcinoma vs. Normal 1.7 p = 0.007
Lobular Breast Carcinoma vs. Normal 1.4 p = 0.022
5. Turashvili et al. (2007) [25] 30 Invasive Ductal Breast Carcinoma vs. Normal 1.3 p = 0.007
Figure 1 Expression pattern of RRBP1 protein in normal and breast cancer tissues. The images
shown here are of the tissue sections from TMAs stained with anti-RRBP1. The panel of four sections on the
top represents normal breast tissue sections showing weak expression of RRBP1 protein. The lower panel
represents four tumor sections that show significant overexpression of the protein. All the images were
taken at 200X magnification.
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visualized. We used a progression TMA to assess the expression of this protein in di-
verse types of benign breast tumors and malignant breast carcinomas. We observed
that the expression of RRBP1 protein showed a definite increase in malignant tumors
when compared to normal, benign and hyperplastic conditions. However, we did not
observe any gradation in the expression of RRBP1 in benign or hyperplastic conditions.
Table 3 shows the pattern of expression of RRBP1 across the cases tested. As shown in
the table, 84% of the tumors showed overexpression of RRBP1. The expression of
RRBP1 in the 16 controls tested showed a weak to moderate cytoplasmic staining. Out
of the 219 cases tested, 177 cases showed positive staining in carcinoma cells alone, 25
cases showed positive staining in tumor as well as the stromal components and 16
cases showed overexpression only in the stroma but not in the tumor cells.Public availability and accessibility of IHC data
To make our observations publicly available and accessible to other researchers, we
have submitted our data on the immunohistochemical analysis of RRBP1 to Human
Proteinpedia (HUPA) [29,30]. The expression of RRBP1 in normal breast epithelium
[31] and in breast cancer [32] can be visualized in separate pages. Figure 2 shows a
screenshot of HPRD molecule page for RRBP1 and also of HUPA resource which is
linked to HPRD, displaying RRBP1 expression in breast cancer.Table 3 Summary of RRBP1 expression pattern in breast cancer tissues
Parameters Number of cases
1. Number of cases tested 259
2. Number of positive cases 219
3. Number of cases with positive staining of carcinoma cells alone 177
4. Number of cases with positive staining of stroma alone 16
5. Number of cases with positive staining of both carcinoma and stromal component. 25
Figure 2 A snapshot of RRBP1 annotation in human Proteinpedia. Shown here is a screenshot of
the HPRD molecule page for RRBP1 protein depicting the gene information, architecture, post-translational
modifications, cellular localization and tissue expression of the molecule. The figure also shows the
immunohistochemical data from this study as displayed in HUPA in the inset.
Telikicherla et al. Clinical Proteomics 2012, 9:7 Page 5 of 8
http://www.clinicalproteomicsjournal.com/content/9/1/7Conclusions
The results we obtained from our experiment show that RRBP1 was significantly upre-
gulated in breast cancers. The unique work plan we followed to close in on RRBP1
protein using online gene expression data repositories, databases that provide protein
information and published literature has proven beneficial in finding candidate bio-
markers in a fast and effective manner. This study highlights the power of a bioinfor-
matics approach coupled to experimental validation. We found RRBP1 as a novel
candidate marker that is significantly overexpressed in invasive breast carcinomas.
However, further analyses across larger sample sets and insights into the functional
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biomarker.Methods
Tissue microarrays
We used two types of TMAs including one breast cancer progression TMA (n = 36)
that was purchased from Creative Biolabs (TMA-029) and custom TMAs (n = 44) that
were prepared by JCR. The custom TMA construction and the use of cases was
approved by the Institutional Review Board (IRB) at the Universidad de La Frontera,
Temuco, Chile.Immunohistochemical staining
Immunohistochemical staining was performed on breast cancer tissue microarrays for
RRBP1. The rabbit polyclonal antibody against RRBP1 was purchased from the Human
Protein Atlas (catalog # HPA009026). Anti-RRBP1 antibody was used at 1:5000 dilu-
tion. An Envision kit (DAKO) was used following the manufacturer’s instructions.
Briefly, tissue microarrays were deparaffinized and antigen retrieval was carried out by
incubating for 20 minutes in antigen retrieval buffer. Endogenous peroxidases were
quenched using the blocking solution followed by three washes with the wash buffer.
The sections were incubated overnight at 4°C in a humidified chamber with the pri-
mary antibody. After washing, the slides were incubated with appropriate horseradish
peroxidase conjugated secondary antibody for 30 minutes at room temperature. Immu-
noperoxidase staining was developed for 5 minutes using DAB chromogen, and coun-
terstained with hematoxylin (Nice Chemicals, India). We used the diluent instead of
primary antibody as the negative control. The images were taken by using LEITZ
DMRB model (Leica Microsystems, Wetzlar, Germany) microscope at a magnification
of 200X. Immunohistochemical labeling was assessed by an experienced expert path-
ologist (JM), and intensity of staining was scored as negative (0), mild (1+), moderate
(2+), or strong (3+). The distribution of staining of cancer cells was scored as 0 (less
than 5% of cells staining), 1+ (5%–30% of cells staining), 2+ (31%–60% of cells staining)
or 3+ (greater than 60% of cells staining). Comparisons were made between the inten-
sity of the staining of carcinoma cells and that of normal breast tissue.
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